A new, highly sensitive cell therapy was able to wipe out three different kinds of solid tumors in mice, an important advance in an area where CAR-T cells have long struggled. But significant ...

A proof-of-concept study opens up an avenue for treating solid tumours that express low levels of a target antigen.

Scientists have discovered that T cell receptors activate through a hidden spring-like motion that had never been seen before. This breakthrough may help explain why immunotherapy works for some ...

Researchers hope to undertake clinical studies in multiple cancers, including ovarian cancer, glioblastoma, and others.

Though CAR T cells have been effective against certain blood cancers, they have not been for solid tumors. Now, a new form of ...

The gray portion of this schematic represents a nanodisc, where for the first time researchers were able to replicate the native membrane environment (red dots) of a T-cell receptor (cyan). One of the ...

T cell receptors (TCRs) are fundamental to the adaptive immune system, playing a pivotal role in recognising and responding to pathogenic challenges. Generated through the process of V(D)J ...

Cemacabtagene ansegedleucel, an allogeneic chimeric antigen receptor (CAR) T-cell therapy, is being investigated in relapsed/refractory large B-cell lymphoma. The investigational allogeneic chimeric ...

A new CAR T therapy design uses the approved drug venetoclax to temporarily disengage engineered immune cells from tumors.

Scientists at École Polytechnique Fédérale Lausanne (EPFL), and at UNIL-CHUV, University Hospital Lausanne (CHUV) and University of Lausanne (UNIL) have developed a computational method to create ...

In 2024, Professor Sebastian Kobold's research group at LMU University Hospital had already shown that the metabolite ...

A type of immune cell targeting the Epstein-Barr virus may play a key role in driving multiple sclerosis (MS), a study found.